You are here
Safety, Pharmacokinetics Trial of BlockAide/CR To Begin
"We were encouraged by preclinical studies that showed BlockAide/CR was safe and active against multiple HIV strains," commented Joan M. Robbins, Ph.D., ADVENTRX Chief Technical Officer. "With toxicities associated with current treatment regimens and viral resistance continuing to be a major problem, there is an indisputable need for alternative treatment options. We are hopeful that BlockAide/CR can address these issues."
BlockAide/CR is a synthetic 15 amino acid peptide, which mimics a portion of HIV-1 that is responsible for entry into the immune system cell. The BlockAide/CR peptide binds to immune system cells, preventing co-receptor interaction necessary for HIV fusion and entry. Since BlockAide/CR binds to immune system cells to inhibit viral entry rather than binding directly to HIV, BlockAide/CR may be less susceptible to problems with viral resistance associated with other viral entry inhibitors and HAART (highly active antiretroviral therapy) drugs.
The clinical study is planned to be conducted at the VA San Diego Healthcare System under the direction of David J. Looney, M.D., Principal Investigator, Veterans Medical Research Foundation. Drug safety and effects on HIV viral load and CD4+ T cell count will be determined.
Source: ADVENTRX Pharmaceuticals, Inc.